Cell Signaling Technology

Product Pathways - Apoptosis

FasL Antibody #4273

Applications Reactivity Sensitivity MW (kDa) Source
W H Endogenous 26, 40 Rabbit

Applications Key:  W=Western Blotting
Reactivity Key:  H=Human
Species cross-reactivity is determined by western blot. Species enclosed in parentheses are predicted to react based on 100% sequence homology.

Protocols

Specificity / Sensitivity

FasL Antibody detects endogenous levels of total FasL protein. The antibody is expected to react with both membrane bound and soluble forms of FasL. No cross reactivity was detected with other family members.

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding proline 134 of human FasL. Antibodies were purified by protein A and peptide affinity chromatography.

Western Blotting

Western Blotting

Western blot analysis of recombinant human FasL (amino acids 134-281, 5 ng) and extracts from SW620 and COLO201 cell lines, using FasL Antibody.

Background

Association of the receptor Fas with its ligand FasL triggers an apoptotic pathway that plays an important role in immune regulation, development, and progression of cancers (1,2). Loss of function mutation in either Fas (lpr mice) or FasL (gld mice) leads to lymphadenopathy and splenomegaly as a result of decreased apoptosis in CD4-CD8- T lymphocytes (3,4). FasL (CD95L, Apo-1L) is a type II transmembrane protein of 280 amino acids (runs at approximately 40 kDa upon glycosylation) that belongs to the TNF family, which also includes TNF-α, TRAIL, and TWEAK. Binding of FasL to its receptor triggers the formation of a death-inducing signaling complex (DISC) involving the recruitment of the adaptor protein FADD and caspase-8 (5). Activation of caspase-8 from this complex initiates a caspase cascade resulting in the activation of caspase-3 and subsequent cleavage of proteins leading to apoptosis. Unlike Fas, which is constitutively expressed by various cell types, FasL is predominantly expressed on activated T lymphocytes, NK cells, and at immune privileged sites (6). FasL is also expressed in several tumor types as a mechanism to evade immune surveillance (7). Similar to other members of the TNF family, FasL can be cleaved by metalloproteinases producing a 26 kDa trimeric soluble form (8,9).

  1. Suda, T. et al. (1993) Cell 75, 1169-78.
  2. Lee, H.O. and Ferguson, T.A. (2003) Cytokine Growth Factor Rev 14, 325-35.
  3. Watanabe-Fukunaga, R. et al. (1992) Nature 356, 314-7.
  4. Hahne, M. et al. (1995) Int Immunol 7, 1381-6.
  5. Nagata, S. (1997) Cell 88, 355-65.
  6. Green, D.R. and Ferguson, T.A. (2001) Nat Rev Mol Cell Biol 2, 917-24.
  7. Walker, P.R. et al. (1997) J Immunol 158, 4521-4.
  8. Kayagaki, N. et al. (1995) J Exp Med 182, 1777-83.
  9. Tanaka, M. et al. (1995) EMBO J 14, 1129-35.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Companion Products

For Research Use Only. Not For Use In Diagnostic Procedures.

Products